Immunome (IMNM) Operating Income Growth (5y) (2024 - 2026)

Immunome (IMNM) Operating Income Growth (5y) (2024 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,861.65 Bn 66,861.36 Bn -
2 Nanobiotix 1,912.79 Bn 1,912.72 Bn -
3 Akari Therapeutics 1,071.19 Bn 1,071.19 Bn -
4 BeOne Medicines 469.11 Bn 464.32 Bn 1.35 Bn
5 Vertex Pharmaceuticals 123.03 Bn 115.78 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 70.13 Bn 61.37 Bn 3.31 Bn
7 Belite Bio 63.44 Bn 63.44 Bn -
8 Argenx Se 55.97 Bn 50.78 Bn 1.41 Bn
9 Alnylam Pharmaceuticals 37.53 Bn 34.52 Bn 959.66 Mn
10 Immunome 2.59 Bn 2.00 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -72.39%
Dec 31, 2025 -78.04%
Sep 30, 2025 -84.43%
Jun 30, 2025 -76.48%
Mar 31, 2025 -75.84%
Dec 31, 2024 -95.73%
Sep 30, 2024 -79.38%